Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03551951 · ClinicalTrials.gov registry record
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
A clinical trial of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- 320
- Enrollment target
- 1
- Study location
NCT03551951 is a study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 320 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03551951, a study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- 320 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies and improve screening.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Test for circulating tumor cells, DNA alterations
Study Locations (1)
Missouri
- Harry S Truman Veterans Memorial Hospital - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2027-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03551951
The ClinicalTrials.gov registry entry for NCT03551951 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Test for circulating tumor cells, DNA alterations is the first listed.
NCT03551951 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03551951 about?
NCT03551951 is a clinical study titled "Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow". Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated ...
What is the current status of trial NCT03551951?
This trial is currently recruiting. The enrollment target is 320 participants. The study started on 2016-07-01. Estimated completion is 2027-12-30.
What conditions does trial NCT03551951 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT03551951?
The interventions under investigation include: Test for circulating tumor cells, DNA alterations (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03551951?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03551951 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.